JP Morgan Maintains Overweight on PTC Therapeutics, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Overweight rating on PTC Therapeutics (NASDAQ:PTCT) and raises the price target from $43 to $53.
May 21, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Eric Joseph has maintained an Overweight rating on PTC Therapeutics and raised the price target from $43 to $53, indicating a positive outlook for the stock.
The raised price target from $43 to $53 by a reputable analyst at JP Morgan suggests increased confidence in PTC Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100